CytomX Therapeutics, headquartered in South San Francisco, California, is a clinical-stage biopharmaceutical company focused on the discovery and development of conditionally activated therapies for the treatment of cancer and other serious diseases. Founded in 2008, the company has built a proprietary Probody® platform that engineers antibody prodrugs designed to remain inactive until they reach the tumor microenvironment. By restricting target engagement to the tumor site, CytomX seeks to enhance the efficacy of antibody therapeutics while minimizing systemic toxicity commonly associated with conventional monoclonal antibodies.
The Probody platform underpins CytomX’s pipeline, which includes multiple therapeutic candidates in various stages of clinical development. These Probody molecules are engineered with masked binding domains that are selectively unmasked by proteases enriched in diseased tissue. Among the company’s lead programs are oncology candidates targeting immune checkpoints and tumor-associated antigens. CytomX’s research and development efforts extend to both monotherapy applications and combination regimens, aiming to address solid tumors with high unmet medical need.
In addition to its internal pipeline, CytomX has forged strategic collaborations and license agreements with leading global pharmaceutical and biotechnology companies. These partnerships span North America, Europe and Asia and allow CytomX to leverage its Probody technology in combination with established oncology and immunotherapy platforms. The company maintains research operations in South San Francisco and collaborates with academic institutions and contract research organizations to advance preclinical research and clinical trial execution worldwide.
Under the leadership of President and CEO T.J. John, CytomX is guided by a management team with extensive experience in drug discovery, clinical development and commercial strategy. The board and scientific advisory committees include seasoned experts in immuno-oncology, protein engineering and translational medicine. As CytomX progresses its novel Probody candidates through clinical milestones, the company remains committed to transforming the safety and efficacy profile of cancer therapies and expanding its technology to address additional therapeutic areas.
AI Generated. May Contain Errors.
Free CTMX Stock Alerts